Lantern Pharma (NASDAQ:LTRN) Director D Jeffrey Keyser Acquires 48,544 Shares

Lantern Pharma Inc. (NASDAQ:LTRN) Director D Jeffrey Keyser acquired 48,544 shares of the stock in a transaction on Tuesday, May 12th. The shares were acquired at an average price of $2.06 per share, for a total transaction of $100,000.64. Following the acquisition, the director owned 94,303 shares of the company’s stock, valued at approximately $194,264.18. The trade was a 106.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Lantern Pharma Stock Up 24.7%

LTRN traded up $0.62 during trading on Thursday, hitting $3.13. 1,252,820 shares of the company’s stock were exchanged, compared to its average volume of 440,871. The business’s 50 day moving average is $2.21 and its two-hundred day moving average is $2.93. Lantern Pharma Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $5.74. The stock has a market cap of $35.38 million, a P/E ratio of -1.99 and a beta of 2.10.

Lantern Pharma (NASDAQ:LTRN) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.10.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. Wall Street Zen upgraded shares of Lantern Pharma to a “sell” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Lantern Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers purchased a new stake in shares of Lantern Pharma in the fourth quarter valued at about $37,000. XTX Topco Ltd purchased a new stake in shares of Lantern Pharma in the second quarter valued at about $40,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Lantern Pharma in the fourth quarter valued at about $47,000. Two Sigma Investments LP purchased a new stake in shares of Lantern Pharma in the third quarter valued at about $70,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Lantern Pharma in the third quarter valued at about $170,000. Hedge funds and other institutional investors own 28.62% of the company’s stock.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.